Infectious Diseases — New This Week — September 4

A mixed week across both journals. CID leads with two practice-relevant items: the GAME CHANGER DOOR/GPC re-analysis confirming that cefiderocol is non-inferior but not superior to standard of care for Gram-negative BSI even by composite endpoints, and a Mayo Clinic cohort showing that antibiotics in hospice are associated with increased mortality — except when an infectious process is the hospice-qualifying condition itself. A WGS study finds no room-level C. difficile transmission when sporicidal disinfectants are used. OFID contributes a large Georgian cohort reaffirming DM and underweight as TB risk factors post-HCV treatment, a small but provocative cross-sectional finding that molecular HPV testing catches what cytology misses in neovaginal tissue, and long-term DTG/fostemsavir follow-up confirming durable responses in MDR HIV. One card this week — the hospice antibiotics stewardship principle.

Clinical Infectious Diseases

CIDAntimicrobials · RCT secondaryHigh yield · ID

GAME CHANGER: Cefiderocol vs Standard of Care for Gram-Negative Bacterial BSI — DOOR and GPC Analysis

In adults with Gram-negative bloodstream infections, does cefiderocol provide a net clinical advantage over SOC when efficacy, safety, and functional outcomes are integrated?

PopulationAdults with healthcare-associated GNB BSI at 17 hospitals in 6 countries (Australia, Malaysia, Singapore, Taiwan, Thailand, Türkiye). Includes a carbapenem-resistant subset. InterventionCefiderocol. ComparisonStandard of care antibiotics (investigator-selected). OutcomeDOOR composite: probability of more desirable outcome with cefiderocol 50.4% (95% CI 45.6–55.1). GPC: win ratio 1.04 (0.85–1.28), NTB 2.1% (−8.0% to 12.2%). Carbapenem-resistant subset: DOOR 46.8% (37.4–56.1), win ratio 0.90 (0.60–1.34). No superiority in either population. What this changesConfirms the primary GAME CHANGER result — cefiderocol is an option for GNB BSI, not a default over SOC. No advantage even with composite outcomes.

Clinical takeaway. This pre-specified DOOR/GPC analysis of the GAME CHANGER trial integrates efficacy, safety, and functional outcomes into a single composite — and still finds no net advantage for cefiderocol over SOC for GNB BSI. The signal is consistent even in the carbapenem-resistant subset (DOOR 46.8%), where clinical intuition might favor a siderophore cephalosporin. Open-label design and heterogeneous SOC regimens are limitations. For the fellow: cefiderocol remains a tool in the toolkit for difficult GNB (especially Acinetobacter and CR Pseudomonas), but data do not support preferring it over well-chosen SOC when susceptibility allows. Not carded — confirmatory secondary analysis.

CIDStewardship · CohortHigh yield · ID

Relationship Between Antibiotic Prescription and Survival in Hospice

In outpatient hospice patients, is antibiotic prescription associated with improved survival — and does it vary by hospice-qualifying condition?

Population6,169 patients with a hospice-qualifying condition enrolled in Mayo Clinic outpatient hospice (2017–2023). 1,233 (20%) received ≥1 antibiotic; median time to first Rx 16 days (IQR 3–83). Key findingAntibiotic use → increased hazard of death (aHR 1.47, 95% CI 1.37–1.57). Cancer HQCs: aHR 1.67 (1.50–1.87). Exception: infectious HQCs — the ONLY subgroup with a survival benefit (aHR 0.60, 95% CI 0.40–0.89). Fellow implicationSymptoms prompting antibiotics in hospice likely reflect terminal decline, not treatable infection. Infectious HQCs are the biologically plausible exception. Supports proactive stewardship counseling: set expectations before the crisis and consider time-limited trials (per Quill) when families request antibiotics.

Clinical takeaway. The editorial (Karlin) argues persuasively that the increased mortality hazard is not antibiotic harm per se but a marker that the dying process has begun — the infection is the terminal event, not a treatable deviation. For cancer patients especially (aHR 1.67), antibiotics cannot reverse immune collapse or malignant obstruction. The exception (infectious HQCs, aHR 0.60) aligns with intuition: when infection IS the life-limiting diagnosis, treating it extends survival. For the ID consultant: lean into goals-of-care conversations before the infection arises, and frame antibiotic limits as stewardship, not callousness. Carded — durable stewardship principle.

CIDInfection Prevention · WGSNotable · single-center

WGS Investigation of C. difficile Transmission From Prior Room Occupants

Does WGS confirm that being admitted to a room previously occupied by a CDI patient increases risk?

Single-center VA cohort (n=5,746 admitted; 55 HA-CDI). Prior room occupancy by a CDI patient was not associated with increased HA-CDI risk (aOR 1.15, 0.65–1.98). Of 21 HA-CDI patients with prior room-level CDI exposure, none had isolates genomically related to prior room occupants or room surfaces by WGS. Five HA-CDI cases were linked to prior CDI patients on the same ward (not room-level). The editorial frames this as potentially reflecting effective sporicidal terminal disinfection rather than absence of the transmission pathway. Editorial

Not carded — single-center VA with small HA-CDI sample (n=55); principle plausible but requires confirmation

Open Forum Infectious Diseases

Notable studies

OFIDBacterial · Q feverNotable · single-center

Chronic Q Fever at Mayo Clinic (2007–2023)

What are the clinical features and diagnostic delays of chronic Q fever in a US tertiary center?

Abstract-only. 33 patients (88% male). Median diagnostic delay 99 days. 42% prosthetic valve endocarditis, 27% vascular graft infection. 75% treated with doxycycline + hydroxychloroquine; 42% required surgery; 6% mortality. 24% had no identifiable exposure history. Confirms known patterns: cardiovascular infection predominates, diagnostic delays are substantial, and doxy+HCQ remains standard.

Not carded — single-center descriptive series; abstract-only; confirms established management patterns

OFIDTB · Nationwide cohortNotable · confirmatory

TB Incidence and Risk Factors After HCV Treatment: A Population-Based Cohort (Georgia)

After successful HCV treatment, what clinical factors predict incident TB?

Nationwide Georgian cohort (n=75,693; 399,504 PY). TB IR 136/100,000 PY. Diabetes independently associated (aIRR 1.53, 1.09–2.07). Underweight BMI strongly associated (aIRR 2.8, 1.67–4.41). Overweight/obese protective (aIRR 0.48/0.21). Advanced liver fibrosis NOT significant. Supports integrating TB screening into HCV care for high-risk subgroups.

Not carded — DM and underweight as TB risk factors are established; confirmatory in the post-HCV population

OFIDHIV · 96-week follow-upNotable · confirmatory

DTG BID and Fostemsavir 96-Week Outcomes in MDR HIV (VIKING-3/BRIGHTE)

How do dolutegravir BID and fostemsavir compare at 96 weeks in heavily treatment-experienced patients?

Post hoc side-by-side of two separate single-arm studies (not randomized). VIKING-3 (DTG BID, n=183): 84% VS at week 96, median CD4 +160. BRIGHTE (FTR, n=272): 79% VS, median CD4 +175. Both well tolerated. Confirms durable long-term efficacy of both agents in MDR HIV.

Not carded — confirmatory long-term data from two previously reported single-arm studies; not a randomized comparison

OFIDVaccines · Claims analysisNotable · observational

PCV13 and Residual Disparities in Pneumonia Hospitalizations Among US Adults

After pediatric PCV13 implementation, do racial and socioeconomic disparities in adult PNA hospitalizations persist?

38.7M US adults (Optum CDM, 2008–2019). Post-PCV13 PNA hospitalizations declined 10–48% by age (largest: 18–49, IRR 0.52). Residual disparities: Black adults 18–49 had nearly 2× the rate vs White (IRR 1.90). At-risk/high-risk: IRR 11.33 vs low-risk (18–49). Lower household income persistent risk factor. Policy-relevant; no new clinical decision point for the individual patient.

Not carded — PCV13 herd benefit established; disparity analysis is policy-level

OFIDHIV · Narrative reviewNotable · narrative review

Integrating Cervical Cancer Prevention into HIV Services in Sub-Saharan Africa

How should cervical cancer screening be integrated into HIV care in SSA, and what vaccine gaps remain?

Narrative review: women with HIV in SSA carry a disproportionate cervical cancer burden (prevalence 4.4–71.8% across countries). HPV35 — highly prevalent in SSA — is NOT covered by Gardasil 9. Screening coverage only 12.87% across SSA. WHO recommends screening at age 25 for women with HIV (vs 30 general). 3-dose HPV vaccination still required for women with HIV (insufficient single-dose data). Integration into HIV care platforms is the most promising strategy.

Not carded — synthesizes established knowledge; no new data or guideline change

OFIDSTI · Cross-sectionalNotable · small n

HPV and STI Screening in Transgender Women with Neovaginas

Should molecular rather than cytologic screening be used for HPV detection in neovaginal tissue?

Cross-sectional (Mexico City, n=16). High-risk HPV detected in 38.5% (5/13) by PCR despite universally negative cytology. HPV 51 and 53 most prevalent. STI co-detections: M. hominis 46.2%, U. parvum 23.1%. No formal guidelines exist for neovaginal HPV surveillance; supports molecular over cytologic screening.

Not carded — n=16, single-center; principle plausible but too small to establish screening recommendations

Also new this week

ID Power Hour (OFID) — Student-led case-writing mentorship initiative at UNMC pairing medical students with ID faculty; 38 students, 19 cases over 2 years. Operational/educational, no clinical data.
IMPAACT 2041: GLE/PIB in Pregnancy (OFID) — Phase I/II trial design for glecaprevir/pibrentasvir PK and safety in pregnant women with HCV (8 weeks, enrollment 14–32 weeks gestation). Study protocol — no results yet.

Anki cards this week

1 card minted (combined CID + OFID; ID-fellow bar, four-gate filter). The hospice antibiotic stewardship principle cleared all four gates. The GAME CHANGER cefiderocol analysis was featured but not carded (confirmatory secondary analysis). All other items: confirmatory, single-center, small n, narrative review, operational, or study protocol. Card staged as TSV for user review.

Original paraphrase & DOI links. Full text via publisher access.
CID: ciag538 · ciag561 · ciag562 · ciag547 · ciag548
OFID: ofag542 · ofag497 · ofag487 · ofag528 · ofag509 · ofag516 · ofag541 · ofag537